High Tumor Mutation Burden Predicts Response to Immune Checkpoint Blockade for Some Cancer Types
High tumor mutation burden (TMB) found it was predictive of clinical responses to immune checkpoint inhibitors for a subset of cancer types.
High tumor mutation burden (TMB) predicts clinical responses to immune checkpoint blockade in a subset of cancers, notably non‑small cell lung cancer (NSCLC), bladder cancer, and melanoma, but not in breast, prostate, or brain cancers.
The finding indicates that TMB can serve as a predictive biomarker for immunotherapy benefit in selected cancer types, guiding personalized treatment decisions and avoiding ineffective therapy in non‑responsive cancers.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT